Preferred Label : Radotinib Hydrochloride;
NCIt synonyms : 4-Methyl-N-(3-(4-methylimidazol-1-yl)-5-trifluoromethylphenyl)-3-(4-(pyrazin-2-yl)pyrimidin-2-ylamino)benzamide
Hydrochloride;
NCIt definition : An orally available, hydrochloride salt form of radotinib, a second-generation tyrosine
kinase inhibitor of Bcr-Abl fusion protein and the platelet-derived growth factor
receptor (PDGFR), with potential antineoplastic activity. Upon administration, radotinib
specifically inhibits the Bcr-Abl fusion protein, an abnormal enzyme expressed in
Philadelphia chromosome positive chronic myeloid leukemia (CML) cells. In addition,
this agent also inhibits PDGFR thereby blocking PDGFR-mediated signal transduction
pathways. The inhibitory effect of radotinib on these specific tyrosine kinases may
decrease cellular proliferation and inhibit angiogenesis. This agent has shown potent
efficacy in CML cells that are resistant to the first-generation standard tyrosine
kinase inhibitors, such as imatinib, nilotinib and dasatinib. PDGFR, upregulated in
many tumor cell types, is a receptor tyrosine kinase essential to cell migration and
the development of the microvasculature.;
UNII : EF516G9REZ;
CAS number : 926037-85-6; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 926037-85-6
alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo
G-SRS /a ;
Drug name : Supect;
Molecule name : IY5511HCl;
Origin ID : C99644;
UMLS CUI : C3274847;
Semantic type(s)
- concept_is_in_subset
- has_free_acid_or_base_form
- is_salt_form_of
